Why UroGen Pharma is looking beyond bladder cancer with IntraGel’s cisplatin-loaded SRGel platform
UroGen Pharma will invest up to $7 million in IntraGel while securing an option on TumoCure and potential rights to three additional SRGel oncology programmes.